Budesonide — An Addition to our Local Therapeutics in the Treatment of Allergic and Vasomotor Rhinitis

Abstract

A new steroid for nasal use, Budesonide, is presented. Earlier studies have shown it to be efficacious compared to placebo in the treatment of allergic rhinitis. In a blind comparison with Beclo-methasone dipropionate, where both drugs were administered in daily 400 μg doses, the effect of budesonide proved to be significantly superior in hay fever treatment. In a long-term study of vasomotor rhinitis, no adverse effect on plasma cortisol and nasal mucosa could be detected after one year of continuous treatment. In a nasal allergen challenge study, a clear effect on the type 1 reaction could be shown after a one-week pretreatment period.